A red blood cell distribution width (RDW) test is an important part of a complete blood count (CBC) test. It measures the range of red blood cell sizes in the body. A high RDW result can indicate anemia, inflammation, or other health conditions. In this article, we will discuss the meaning of a high RDW result, and its potential implications.
RDW is a measure of the range of red blood cell sizes in the body. It is usually expressed as a percentage. The size of red blood cells can vary from person to person, but a high RDW result indicates that the size of the red blood cells is unusually wide.
A high RDW result can indicate a number of possible health conditions. It can be a sign of anemia, which is a condition in which the body does not have enough healthy red blood cells. It can also be a sign of inflammation, which is a response of the body to infection or injury. In some cases, it can be a sign of a vitamin B12 or folate deficiency.
If a high RDW result is found on a CBC test, further tests may be needed to diagnose the cause. These tests may include a ferritin test to check for anemia, a C-reactive protein test to check for inflammation, and a vitamin B12 and folate test to check for deficiencies.
The treatment for a high RDW result will depend on the underlying cause. If the cause is anemia, iron supplements may be prescribed to increase the number of healthy red blood cells in the body. If the cause is inflammation, anti-inflammatory medication may be prescribed. If the cause is a vitamin B12 or folate deficiency, supplements may be prescribed.
A high RDW result can be a sign of several different health conditions. It is important to discuss any abnormal results with a doctor, who can order further tests to diagnose the cause. Depending on the underlying cause, treatment may involve iron supplements, anti-inflammatory medication, or vitamin B12 or folate supplements.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation